Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Spire Healthcare H1 revenues grow on strong NHS demand

(Sharecast News) - Healthcare group Spire Healthcare said on Wednesday that H1 revenues had grown amid strong NHS demand and strategic pricing across its hospital network. Spire said interim revenues had grown 4.9% to £796.7m, while adjusted underlying earnings rose 2.8% to £133.8m, though margins dipped slightly to 16.8% due to National Insurance and minimum wage increases.

Hospital revenues climbed 4.7% to £732.3m, with NHS income up 16.2% year-on-year, reflecting a shift toward higher-acuity procedures. Private patient revenues edged up 0.8%, while primary care revenue grew 6.5% to £64.4m, supported by new contracts and acquisitions.

Adjusted operating profits were broadly flat at £76.0m, while adjusted pre-tax profits dropped 11.2% to £23.8m and statutory pre-tax profits halved to £10.8m, impacted by £13.0m in restructuring costs.

However, Spire still opted to reaffirm FY guidance, including mid-single-digit revenue growth and adjusted EBITDA of £270-285m.

Chief executive Justin Ash said: "We have delivered performance in line with expectations in the first half of the year and are on track to do so in the second half. Our business continues to operate successfully in a fast-changing market.

"The market will remain dynamic and challenging throughout H2, but our ability to use all the levers at our disposal to flex what we offer our patients and payors, and where we offer it, is the highest it has ever been."

As of 0855 BST, Spire shares were up 0.44% at 226p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.